A 32-year-old man from rural Maharashtra presents with a 6-month history of hypopigmented macules over his face, trunk, and extremities. On examination, sensory loss is demonstrated over the lesions. Slit-skin smear shows 4+ acid-fast bacilli. He is started on multidrug therapy (MDT) for lepromatous leprosy. After 3 weeks of treatment, he develops acute inflammation of existing lesions with fever, painful nodules, and worsening of skin lesions. Which of the following best explains this clinical phenomenon?

Explanation

## Clinical Presentation Analysis The patient has lepromatous leprosy (high bacillary load: 4+ AFB) and develops acute inflammation with painful nodules, fever, and worsening lesions **within 3 weeks of starting MDT**. This timing and presentation are pathognomonic for **Type 2 lepra reaction (Erythema Nodosum Leprosum, ENL)**. ## Type 2 Lepra Reaction (ENL) **Key Point:** ENL is an immune complex-mediated reaction (Type III hypersensitivity) that occurs in **lepromatous and borderline lepromatous leprosy** patients, typically 1–2 years after starting treatment, but can occur within weeks in highly bacillated cases. ### Pathophysiology 1. Antigen-antibody complexes form as bacillary antigens are released during drug-induced bacterial death 2. Immune complexes deposit in skin, nerves, eyes, and kidneys 3. Complement activation → acute inflammation 4. Occurs **despite clinical improvement** in bacillary load ### Clinical Features of ENL - **Skin:** Painful, tender nodules (not the original lesions) - **Systemic:** Fever, malaise, lymphadenopathy - **Extracutaneous:** Neuritis, iritis, orchitis, glomerulonephritis - **Timing:** Can occur before, during, or up to years after MDT - **Bacillary load:** Occurs in high-bacillary cases (LL, BL) **High-Yield:** ENL is **NOT** a sign of treatment failure — it reflects immune reconstitution and bacterial antigen release. Continuing MDT is essential; adding corticosteroids or thalidomide manages the reaction. ## Differential: Type 1 Lepra Reaction (Reversal Reaction) | Feature | Type 1 (Reversal) | Type 2 (ENL) | |---------|-------------------|---------------| | **Hypersensitivity** | Type IV (DTH) | Type III (Immune complex) | | **Leprosy type** | Borderline forms (BT, BL, BB) | LL, BL (high bacillary) | | **Timing** | Months to years after MDT | Weeks to years; often early | | **Lesion change** | Existing lesions inflame | New nodules appear | | **Systemic symptoms** | Minimal | Fever, constitutional | | **Bacillary load** | Low to moderate | High (4+) | | **Management** | Corticosteroids alone | Corticosteroids + thalidomide | **Clinical Pearl:** In a patient with **4+ AFB (lepromatous)** who develops **painful nodules and fever early in treatment**, always think ENL first. ## Management of ENL 1. **Continue MDT** — do not stop antileprotic drugs 2. **Corticosteroids** — prednisolone 0.5–1 mg/kg/day, taper over weeks 3. **Thalidomide** — 100–300 mg/day for steroid-resistant or recurrent ENL (teratogenic; strict contraception required) 4. **NSAIDs** — for mild cases 5. **Monitor renal function** — screen for glomerulonephritis [cite:KD Tripathi 8e Ch 47]